PDS Biotechnology Corporation Common Stock
PDSBPDS Biotechnology Corporation (PDSB) is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and infectious diseases. The company leverages its proprietary Versamune® platform to stimulate the body's immune response and has a portfolio of product candidates targeting various cancers and infectious diseases. Based in the United States, PDS Biotechnology aims to create innovative treatments with the potential for durable immune responses.
Company News
PDS Biotechnology announced a registered direct offering of 5.8 million shares and warrants, expecting to raise $5.3 million upfront with potential additional $5.8 million from warrant exercises. The proceeds will support the VERSATILE-003 Phase 3 clinical trial and other research and development expenses.
PDS Biotechnology reported a Q2 2025 net loss of $0.21 per share, beating analyst expectations. The company continues advancing its immunotherapy platforms in oncology and infectious disease, with notable progress in clinical trials for HPV and colorectal cancer treatments.
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Over the past 3 months, 4 analysts have published their opinion on PDS Biotechnology (NASDAQ:PDSB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish ...
PDS Biotechnology reports positive results in the phase 2 study of PDS0101 with Keytruda for head and neck cancer and plans for the phase 3 study. Find out why PDSB stock is a Buy.
